key: cord-0914916-fkcdg6m0
authors: Hemmati, Farshad; Hemmati-Dinarvand, Mohsen; Karimzade, Marziye; Rutkowska, Daria; Eskandari, Mohammad Hadi; Khanizadeh, Sayyad; Afsharifar, Alireza
title: Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2
date: 2021-11-27
journal: Biotechnol Lett
DOI: 10.1007/s10529-021-03211-0
sha: 2c44d5935506744b63c6a0a365bc7cda4c080b3b
doc_id: 914916
cord_uid: fkcdg6m0

After its emergence in late 2019 SARS-CoV-2 was declared a pandemic by the World Health Organization on 11 March 2020 and has claimed more than 2.8 million lives. There has been a massive global effort to develop vaccines against SARS-CoV-2 and the rapid and low cost production of large quantities of vaccine is urgently needed to ensure adequate supply to both developed and developing countries. Virus-like particles (VLPs) are composed of viral antigens that self-assemble into structures that mimic the structure of native viruses but lack the viral genome. Thus they are not only a safer alternative to attenuated or inactivated vaccines but are also able to induce potent cellular and humoral immune responses and can be manufactured recombinantly in expression systems that do not require viral replication. VLPs have successfully been produced in bacteria, yeast, insect and mammalian cell cultures, each production platform with its own advantages and limitations. Plants offer a number of advantages in one production platform, including proper eukaryotic protein modification and assembly, increased safety, low cost, high scalability as well as rapid production speed, a critical factor needed to control outbreaks of potential pandemics. Plant-based VLP-based viral vaccines currently in clinical trials include, amongst others, Hepatitis B virus, Influenza virus and SARS-CoV-2 vaccines. Here we discuss the importance of plants as a next generation expression system for the fast, scalable and low cost production of VLP-based vaccines.

Coronaviruses (CoVs) are a major group of viruses belonging to the family Coronaviridae that cause a wide spectrum of diseases. The early twenty-first century has experienced the unprecedented spread of previously unknown, deadly coronaviruses (Song et al. 2019) . CoVs infect the gastrointestinal, respiratory, hepatic, and central nervous systems of humans, birds, livestock, mouse, bat, and many other wild animals (Chen and Guo 2016; Ge et al. 2013; Wang et al. 2006) . SARS-CoV emerged as a new human infection in South China in November 2002 and ended in July 2003. It infected 8096 people and caused 774 deaths with an overall mortality rate of about 9.6% (Drosten et al. 2003; Ksiazek et al. 2003) . MERS-CoV, another highly pathogenic CoV, first emerged in Saudi Arabia, caused a total of 2494 laboratory-confirmed cases of infection and 858 deaths in 27 countries (mortality rate, 34.4%) since September 2012 (http://www.who. int/emergencies/mers-cov/en/) (Hemida 2020 ). These two highly pathogenic betacoronaviruses (b-CoVs) have posed a substantial threat to public health (Han et al. 2020) . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from China in December 2019 and has since been reported all over the world with more than 124,000,000 confirmed cases and 2,730,000 deaths up to 22 March 2021 (https://www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports/; https://www. worldometers.info/coronavirus/). (Hemmati et al. 2020) . In comparison with the H1N1 Influenza virus that has a 0.02% mortality rate, SARS-CoV-2 has a mortality rate of 3% (Rosales-Mendoza 2020). A number of therapeutic options for the treatment of SARS-CoV-2 have been proposed (Li and Clercq 2020) however, vaccination remains one of the most effective strategies in the prevention of new coronavirus virus epidemics (He and Jiang 2005) .

SARS-CoV-2 is an enveloped, positive-sense, single-stranded linear RNA betacoronavirus with a genome ranging from 26 to 32 kb in length (the largest viral RNA genome known) (Armbruster et al. 2019) . Similar to SARS and MERS, the SARS-CoV-2 genome encodes structural proteins [e.g., spike glycoprotein (S)], non-structural proteins (e.g., 3-chymotrypsin-like protease, papain-like protease, helicase, and RNA-dependent RNA polymerase), and accessory proteins. These five proteins were recognized as attractive targets for developing vaccines and other antiviral agents against SARS and MERS (Fehr and Perlman 2015; Han et al. 2020; Malik et al. 2020) . The spike glycoprotein (S) forms homotrimers that are presented on the surface of the virion resulting in the typical coronavirus crown-like appearance. This S protein is indispensable for virus-cell receptor interactions during viral entry (Mahmood et al. 2021; Zumla et al. 2016) and is the major antigen capable of eliciting protective immune responses (Du et al. 2009; Gralinski and Menachery 2020) . It is therefore not surprising that the S protein has been the most appealing target protein included in the 12 vaccines that have received authorization for use in at least one region (Funk et al. 2021) . Among these are a lipid nanoparticle-encapsulated mRNA vaccine and recombinant adenovirus-vectored vaccine expressing the S protein (Folegatti et al. 2020; Mulligan et al. 2020) . Subunit vaccines containing individual SARS-CoV-2 antigens as well as viruslike particle (VLP)-based vaccines presenting antigens in multiarrays on their surfaces are also being developed and are being tested in clinical trials (Capell et al. 2020; Ward et al. 2020; Palca 2020, Novavax.com,) . The recent emergence of neutralization-resistance SARS-CoV-2 variants (Williams and Burgers 2021) necessitate the employment of vaccine expression systems that allow for the rapid production of relevant vaccines at a low-cost ensuring vaccine availability to even resource constrained developing countries (Fuenmayor et al. 2017; Giddings 2001; Loh et al. 2017; Twyman et al. 2003) .

Virus-like particles (VLPs) are self-assembled structures from viral antigens that mimic the three-dimensional, morphological structure of virions but lack the viral genome (Grgacic and Anderson 2006; Kushnir et al. 2012 ). Due to their similarity with the native virion in terms of size, shape, and the repetitive array of immunogenic epitopes displayed on the VLP surface, VLPs, like native virions, can induce potent cellular and humoral immune responses without adjuvant (Bachmann and Jennings 2010; Chackerian 2007; Ge et al. 2013; López-Macías 2012; Roldao et al. 2010) . Due to particulate nature and size, VLPs interact and are taken up by dendritic cells (DC's) and which then process and present the thousands of epitopes a single VLP contains on MHC class I/II molecules inducing a potent T-cell mediated immune responses (Chackerian 2007; Roldao et al. 2010) . The high density display of epitopes in repetitive arrays on the surface of VLPs are also able to elicit high titre and durable B-cell immune responses in the absence of adjuvants (Bachmann et al. 1993; Fehr et al. 1998) .

VLPs also present a safer alternative to the current generation of live, attenuated or inactivated vaccines due to their lack of viral nucleic acid and are thus noninfectious (Marsian and Lomonossoff 2016) . In addition, antigens being presented in their native conformation on the surface of a VLP are more stable than in a subunit form resulting in smaller and less frequent doses of the antigen required to elicit a protective immune response (Chen and Lai 2013) .

The intrinsic characteristics of VLPs have made them into one of the most successful recombinant vaccine platforms. VLP-based vaccines that have been approved by regulatory agencies and are available on the commercial market include those against human papillomavirus virus (HPV) (Cervarix TM by GlaxoSmithKline and Gardasil Ò and Gardasil9 Ò by Merck), composed of the HPV major capsid protein L1, and against hepatitis B virus (HBV) (Energix Ò GlaxoSmithKline and Recombivax Ò by Merck) composed of hepatitis B surface antigen (HBsAg). These vaccines have been shown to be highly effective and safe in humans and capable of inducing long-lasting humoral immune responses These vaccines can induce long-lasting immune responses due to the induction of antibodies that are highly effective and safety profiles in humans (Chackerian 2007; Ge et al. 2013 ). These successes have encouraged the development of VLPbased vaccines against a wide variety of other diseases. However, the high costs associated with the yeast and insect cell expression systems that produce the HPV and HBV vaccines preclude the widescale use of these vaccines in developing countries (Waheed et al. 2012) .

Current VLP expression platforms include bacterial, yeast, insect, mammalian cell culture and more recently, plants, with the yeast, insect and mammalian systems used for commercial production (Chen and Lai 2013) . Each system has its unique advantages and limitations and the choice of platform is usually dependent on the structure and function of the VLPs produced, the scalability and cost of the production process (Gecchele et al. 2015) . The use of Escherichia coli bacteria is widespread due its rapid growth rate and simplicity, which allows recombinant proteins to be produced in less than a day. However, the inability to perform glycosylation and other post-translational protein modifications which are critical in the correct protein folding and assembly of VLPs preclude the use of bacterial expression for VLPs (Edman et al. 1981; Ma et al. 2005; Yao et al. 2015) . The presence of bacterial endotoxins that require removal post production is also a major drawback. In yeast cells glycosylation is mostly limited to inconsistent high mannose glycoforms (Wildt and Gerngross 2005) which is not optimal for the assembly of many VLPs. The simple post translational modifications (high mannose glycosylation), as well as coproduction of baculovirus particles, are limitations of the insect cell expression system (Chen and Lai 2013; Demain and Vaishnav 2009; Loh et al. 2017) . The most optimal environment for authentic post-translational protein modifications and correct VLP assembly are mammalian cell cultures. However, significant capital investment to set up a manufacturing facility, significantly higher production costs and well as contaminating adventitious human pathogens in the cultures are significant drawbacks to this production system (Chen 2008) . Indeed, all cell-culture-based production systems require the building of new facilities and fermentation tanks for large scale production creating challenges in scalability. Plants, however, are inexpensive to grow on a large scale in greenhouses or bioreactors, and have been investigated for the last 20 years for the production of therapeutics for humans and animals (Lico et al. 2008; Ma et al. 2003; Twyman et al. 2003) .

Current plant expression systems enable the production of large quantities of recombinant protein with post-translational modifications allowing for VLP assembly, at low cost and at low risk of introducing adventitious human pathogens (Faye and Gomord 2010) . Early attempts at VLP production in plants had several drawbacks including low yields and a very slow production process which involved the production of stable transgenic plants (Davies 2010) . The recent development of plant virus-based transient expression systems, depicted in Fig. 1 , have greatly increased VLP production speed and yield (Marsian and Lomonossoff 2016) .

Deconstructed viral vectors, based on Tobacco Mosaic virus (TMV), the Cowpea Mosaic virus (CPMV), Potato virus X and Bean yellow dwarf geminivirus, are delivered into plants by Agrobacterium allowing for the fast expression of recombinant proteins at high yields and allowing for highly scalable, GMP-complying industrial processes (Salazar-González et al. 2015) . The TMV RNA replicon (the Magnicon) system (Huang et al. 2009 ), CPMV RNA replicon (the pEAQ) system (Sainsbury and Lomonossoff 2008) and the geminiviral DNA replicon system based on bean yellow dwarf virus (BeYDV) ) are popular transient expression systems that could be used for the rapid expression and assembly of VLP vaccines against viruses that mutate their surface antigens rapidly, like coronaviruses.

N-glycosylation of proteins in plants is similar to that in mammalian cells however, plant-specific b-1,2xylose and core a-1,3-fucose residues are added to complex N-linked glycans and no terminal b1,4-gal and N-acetylneuraminic acid (Neu5Ac) residues are added . These minor differences between plant and mammalian cell protein glycosylation were previously thought to be capable of reducing efficacy of plant-produced vaccines and/or eliciting allergic adverse side-effects in immunized individuals (Chen and Lai 2013) . Recent studies in 14,000 people immunized with plant-derived influenza vaccine candidates indicate no allergic-type reaction to these plant-produced influenza VLPs presenting plant glycosylation (Ward et al. 2014) . Plant-specific glycosylation thus does not interfere with the proper folding and assembly of the influenza VLPs which are also immunogenic. 'Humanized' plant lines, which have been genetically modified to eliminate plant-specific glycans and/or introduce mammalian-specific glycosylation, produce proteins with specific mammalian glycoforms including high mannose, GnGn, G0-G2 galactose, bisected GlcNAc, fucosylated and nonfucosylated and terminal sialic acid addition with a high degree of glycan uniformity (Castilho et al. 2011 (Castilho et al. , 2008 Cox et al. 2006; Gomord et al. 2010; Schähs et al. 2007; Strasser et al. 2009 Strasser et al. , 2008 .

Advantages of the current plant transient expression systems are thus appropriate glycosylation of the expressed proteins resulting in proper folding and assembly of VLPs, rapid rate of protein production, high protein yields, high scalability, low cost and increased safety due to the low risk of adventitious (Chen and Lai 2013) . Unlike other expression systems, a plant-based system does not require expensive equipment for start-up and operation so that the cost of production based on the plant system has reduced to 0.1% of the mammalian cell culture system and 2-10% of microbial systems (Yao et al. 2015) . Plants are photoautotrophs, easy to grow, and require no advanced equipment, thus they can be easily cultivated and produced in large numbers. Moreover, plants can make complex proteins with structures that are naturally similar to spider silk, collagen, and secretory immunoglobulin A (Tschofen et al. 2016) . Moreover, plants are free of endotoxins, oncogenes, and mammalian pathogens, therefore, they are safe and exempt from the costs of refinement and product screening. More than 25 plant-expressed pharmaceuticals have been developed and evaluated in the clinical trials (Loh et al. 2017) . It is thus not surprising that commercial companies have successfully developed a number of plant-expressed pharmaceutical vaccines and therapeutics (Table 1) .

Several VLPs have been developed as vaccine candidates in plants since plant expression systems were introduced. Hepatitis B virus (HBV), human papillomavirus (HPV), influenza virus, SARS-CoV-2, Norwalk virus, human immunodeficiency virus, foot-andmouth disease virus, Rotaviruses, Bluetongue virus, and hepatitis C virus VLPs have all been assembled as vaccines in plants ( C Thuenemann et al. 2013; D'Aoust et al. 2008; Mason et al. 1996; Meyers et al. 2008; Pan et al. 2008; Saldaña et al. 2006; Santos et al. 2005; Scotti et al. 2009; Ward et al. 2021) . In this review we will discuss in detail the plant-produced vaccines against HBV, HPV, Influenza and SARS-CoV-2. HBV HBV VLPs have been widely studied in the last two decades. HBV VLPs were first assembled in yeast in 1984 and induced a good immune response as a vaccine candidate (McAleer et al. 1992) . Two commercial vaccines, Recombivax Ò and Energix Ò , based on HBV VLPs, are produced in yeast expression systems. Arntzen's group first demonstrated the possibility of producing VLPs in plants in 1992. They expressed the hepatitis B core antigen (HBcAg) in tobacco and assembled 22-nm HBV VLPs capable of inducing an immune response in mice (Mason et al. 1992; Thanavala et al. 1995) . More recently, HBV VLPs have been generated through the expression of HBcAg in transient expression systems mediated by expression vectors such as pEAQ in Nicotiana benthamiana plants Mechtcheriakova et al. 2006; Peyret et al. 2019; Peyret and Lomonossoff 2013) . These VLPs are morphologically and immunogenically quite similar to yeast-or E. coliderived HBV VLPs ).

Due to their particulate nature and ability to display epitopes on their surface in a dense repetitive array, HBV VLPs are capable of eliciting strong cellular and humoral immune responses whilst presenting no cytotoxicity in humans (Francis et al. 1990 ). Indeed in recent years there has been a great deal of interest in utilizing plant expressed HBV VLPs as carriers of immunogenic epitopes or peptides for vaccine development (Roose et al. 2013 ).

Researchers discovered that the expression of main capsid protein of HPV (L1) in enabled the formation of VLPs and consequently two commercial HPV L1based VLP vaccines, Gardasil Ò and Cervarix TM , were produced in yeast and insect cells, respectively (Biemelt et al. 2003) . However, the high cost of producing HPV VLPs in these expression system encouraged researchers to produce these VLPs in plants. At first, VLPs were produced by stable transgenic methods in potato and tobacco plants and were found to be similar in shape and size to commercially produced VLPs, but the yield was low. Transient expression with MagnICON vectors in N. benthamiana, however, increased the VLP yield to more acceptable levels (Chen and Lai 2013) . HPV VLPs have also been produced in tobacco leaves using pEAQ vector (Matić et al. 2012) . Studies have shown that plant-derived HPV VLPs are as effective as commercial vaccines in stimulating the immune system of animal models (Chen and Lai 2013) .

Influenza virus haemagglutinin protein (HA) when expressed in plant expression systems assembles into VLPs. Medicago has harnessed this technology to produce about ten million doses of VLP-based H1N1 Influenza vaccine in 1 month according to Phase I cGMP regulations (www.darpa.mil/NewsEvents/ Releases/2012/07/25.aspx). This company is currently the front runner worldwide in the production of plant-based influenza VLPs. Monovalent VLP-based vaccines were first developed and produced as a response to the H7N9 and H5N1 flu pandemics and were subsequently followed by the development of a plant-expressed quadrivalent HA-based VLP to fight seasonal flu, which has successfully completed the phase 1, 2, and 3 clinical trials (Pillet et al. 2016 (Pillet et al. , 2019 . Recently, two phase 3 trials have shown that plant-based HA VLPs provide better protection in adults against influenza viruses compared with commercial flu vaccines that derived from eggs (Ward et al. 2020 ). In addition, it has been shown that HAonly VLPs produced in plants afforded protection to participants in Phase I/II clinical trials while no negative effects on immune reactions or aggravation of plant-based allergies were observed due to plantderived glycosylation (Ward et al. 2014) . Although, there has been much success achieved with the HA protein, other Influenza virus proteins such as M1 Matrix protein, NA neuraminidase, and the NP nucleoprotein remain to be explored as vaccine candidates due to their more conserved natures. https:// kentuckybioprocessing. com/ VLP Virus-like particle, SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2, IgG Immunoglobulin G SARS-CoV-2

Following the success of its production of influenza virus VLPs in plants, Medicago has, through its platform and acquired knowledge, developed a SARS-CoV-2 VLP-based vaccine in plants, and is currently at the forefront of SARS-CoV-2 vaccine development.

The SARS-CoV-2 spike gene sequence was introduced into N. benthamiana plants with agrobacteriummediated transformation. Following expression of the desired protein SARS-CoV-2 VLPs assembled which was quite similar in size and shape to the native SARS-CoV-2 virions (Fig. 2) (Ward et al. 2021 ). This VLPbased SARS-CoV-2 vaccine candidate has shown to be successful in phase I human clinical trials and is currently undergoing phase 2 and 3 clinical trials and is estimated to be produced at a rate of 10 million doses per month (Rosales-Mendoza 2020; Phillip, International 2020).

VLPs may also act as a presentation system for the display of heterologous epitopes to the immune system. Foreign epitopes are coupled to the capsid proteins on the surface of VLPs either by genetic fusion or chemical conjugation and presented in high density repetitive arrays (Chen and Lai 2013) . These chimeric VLPs (cVLPs) protect the presented antigen and enhance immune cell uptake and stimulation due to their particulate nature and high density epitope presentation (Acosta-Ramírez et al. 2008; Lacasse et al. 2008; Manayani et al. 2007; Maurer et al. 2005; Plummer and Manchester 2011; Work et al. 2008) . Although a more stable bond is generated between VLP and antigen via genetic fusion, it cannot be predicted with certainty whether chimeric VLPs will assemble properly, the assembly being dependent on factors such as peptide insert length and charge (Bendahmane et al. 1999) . However a number of foreign epitopes have been successfully been inserted into domains of HBcAg, HBsAg and HIV proteins that are dispensable for VLP assembly or fused to the N-or C-termini of VLP capsid proteins (Chen and Lai 2013) . In order to overcome the limitations of insert size and charge on the correct assembly of chimeric VLP, chemical conjugation of the target antigen to the native VLP is performed. Antigens are linked to the VLPs either through covalent bonds i.e. cysteinelysine linkages (Lechner et al. 2002) or noncovalent bonds i.e. streptavidin-biotin interaction (Chackerian et al. 2006) . The specific interaction between Staphylococcus aureus protein A and the antibody constant fragment can also be exploited (Werner et al. 2006 ). In the last two decades, HBcAg VLPs have been one of the most widely used platforms for the presentation of foreign antigens. The antigens of a number of pathogens such as foot-and-mouth-disease virus (FMDV), hepatitis C virus (HCV), hepatitis B Fig. 2 Comparison of SARS-CoV-2 VLP made by Medicago with wild-type SARS-CoV-2 (Ward et al., 2021) https://www. medicago.com/en/). SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2, VLP Virus-like particle; (Left) Wildtype SARS-CoV-2; (Right) Medicago's Plant-Derived VLP of SARS-CoV-2 virus (HBV), and HIV have been displayed using chimeric HBcAg VLPs (Chen and Li 2006; Clarke et al. 1987; Malik et al. 2012; Stahl and Murray 1989; Ulrich et al. 1992; Yang et al. 2005; Zhang et al. 2007; Zheng et al. 2016) . Chimeric HBcAg VLPs presenting antigens from Dengue virus, Hepatitis E virus (HEV), Human papilloma virus (HPV), Influenza virus, malaria parasite, West Nile virus (WNV) and Zika virus have been expressed in plants (Buonaguro et al. 2011; Chen et al. 2011; Diamos et al. 2019 Diamos et al. , 2020 Pang et al. 2019; Ponndorf et al. 2021; Ravin et al. 2012; Santi et al. 2006; Yang et al. 2017; Zahmanova et al. 2021) . Also produced in plants are chimeric hepatitis B surface antigen (HBsAg) VLPs presenting antigens from HCV, HIV as well as the entire GFP protein (Greco et al. 2007; Huang and Mason 2004; Mohammadzadeh et al. 2020) .

Another well researched epitope presentation platform are chimeric HPV VLPs (Lee et al. 2012; Schellenbacher et al. 2009; Slupetzky et al. 2001; Varsani et al. 2003) . Chimeric HPV CLPs produced in plants have been used to display Influenza epitopes and HPV epitopes, amongst others (Chabeda et al. 2019; Rosa et al. 2009; Matić et al. 2011) .

Plant virus particles (PVPs) offer similar advantages to VLPs in enhancing safety, immunogenicity, yield and stability of presented antigens (McCormick and Palmer 2008; Plummer and Manchester 2011; Sainsbury and Lomonossoff 2008) . PVPs from Cowpea mosaic virus (CPMV), tobacco mosaic virus (TMV), cucumber mosaic virus (CMV), alfalfa mosaic virus, potato virus X (PVX), and papaya mosaic virus (PapMV) have been studied extensively (Brennan et al. 1999; Chichester et al. 2018; Attar et al. 2004; Jiang et al. 2006; Lacasse et al. 2008; Liu et al. 2005; Pulcini et al. 2013; Wang et al. 2007 (Babin et al. 2013; Carignan et al. 2015; Denis et al. 2007; Laliberté-Gagné et al. 2019; Thérien et al. 2017) . Plant expressed chimeric Cowpea mosaic virus (CPMV) PVPs have been used for the display of HIV epitopes (McLain et al., 1996) as well as more recently SARS-CoV-2 epitopes (Chung et al. 2020) .

Formulating epitope-based vaccines is an option to reduce the risk of disease enhancement in SARS-CoV-2 infection (Venkataraman et al. 2021) .

Virus-like particles (VLPs) have been shown to have a number of advantages over traditional and recombinant subunit vaccines including enhanced safety when compared to attenuated and inactivated vaccines and improved immunogenicity and stability when compared to subunit vaccines. When expressed in plant transient expression systems the additional advantages of VLPs include proper eukaryotic modification and assembly, high scalability for high yields, decreased cost for improved product accessibility to developing countries, increased safety due to the lack of contaminating human pathogens, as well as the production speed required to control the outbreak of pandemics, such as SARS-CoV-2.

Several pharmaceutical companies have specialized in producing plant pharmaceuticals and vaccines and efficient, scalable, cost-effective and cGMPcompliant processes have been developed to recover VLPs from plants (Chen and Lai 2013) . Although the regulatory hurdle of FDA approval for plant-expressed VLPs still need to be overcome, the great strides accomplished by the plant-produced influenza and SARS-CoV-2 VLP-based vaccine candidates currently in Phase I, II and III clinical trials suggests that the registration of these products, and consequently acceptance of other plant-produced therapeutics and vaccines, is within reach.

Ethical approval This article does not contain any studies with animals performed by any of the authors. 

Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus

Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies

Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

The influence of antigen organization on B cell responsiveness

Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions

Production of human papillomavirus type 16 virus-like particles in transgenic plants

Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses

Developments in virus-like particle-based vaccines for infectious diseases and cancer

Zika virus-derived E-DIII protein displayed on immunologically optimized VLPs induces neutralizing antibodies without causing enhancement of dengue virus infection

Potential applications of plant biotechnology against SARS-CoV-2

Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine

Construction of a functional CMP-sialic acid biosynthesis pathway in Arabidopsis

In planta protein sialylation through overexpression of the respective mammalian pathway

N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans

Substitution of human papillomavirus type 16 L2 neutralizing epitopes into L1 surface loops: the effect on virus-like particle assembly and immunogenicity

Virus-like particles: flexible platforms for vaccine development

Virus and viruslike particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-b without concomitant T cell responses

Expression and purification of pharmaceutical proteins in plants

Molecular mechanisms of coronavirus RNA capping and methylation

Plant-derived virus-like particles as vaccines

Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier

Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants

Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a phase 1 dose-escalation study in healthy adults

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice

Commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects

An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice

Production of recombinant proteins by microbes and higher organisms

Immunogenicity of papaya mosaic virus-like particles fused to a

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

Synthesis of hepatitis B surface and core antigens in E. coli

Expression of chimeric HCV peptide in transgenic tobacco plants infected with recombinant alfalfa mosaic virus for development of a plant-derived vaccine against HCV

Success stories in molecular farminga brief overview

Coronaviruses: an overview of their replication and pathogenesis Coronaviruses

T cellindependent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Immunological properties of hepatitis B core antigen fusion proteins

Production of viruslike particles for vaccines

Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

A comparative analysis of recombinant protein expression in different biofactories: bacteria, insect cells and plant systems

Transgenic plants as protein factories

Plant-specific glycosylation patterns in the context of therapeutic protein production

Return of the coronavirus: 2019-nCoV

Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine

Virus-like particles: passport to immune recognition

Coronavirus 2019-nCoV: a brief perspective from the front line

Vaccine design for severe acute respiratory syndrome coronavirus

The middle east respiratory syndrome coronavirus (mers-cov) animal-origin viral zoonoses

Mysterious virus: a review on behavior and treatment approaches of the novel coronavirus, 2019-nCoV

Conformational analysis of hepatitis B surface antigen fusions in an agrobacterium-mediated transient expression system

Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice

A DNA replicon system for rapid high-level production of virus-like particles in plants

A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco

A novel coronavirus associated with severe acute respiratory syndrome

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

Novel plant virusbased vaccine induces protective cytotoxic T-lymphocytemediated antiviral immunity through dendritic cell maturation

Increased immunogenicity of full-length protein antigens through sortase-mediated coupling on the PapMV vaccine platform

Virus-like particles as a modular system for novel vaccines

Delivery of chimeric hepatitis B core particles into liver cells

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Coronavirus infections and immune responses

Viral vectors for production of recombinant proteins in plants

Cowpea mosaic virus-based systems for the production of antigens and antibodies in plants

Using transgenic plants and modified plant viruses for the development of treatments for human diseases

Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic

The production of recombinant pharmaceutical proteins in plants

Molecular farming for new drugs and vaccines: current perspectives on the production of pharmaceuticals in transgenic plants

Plant-based drugs and vaccines for COVID-19

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAgspecific T cells and preS1-specific antibodies

Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments

A viral nanoparticle with dual function as an anthrax antitoxin and vaccine

Molecular pharming-VLPs made in plants

Expression of hepatitis B surface antigen in transgenic plants

Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice

Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants

Comparative analysis of recombinant human papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity

Human hepatitis B vaccine from recombinant yeast

Genetically engineered tobacco mosaic virus as nanoparticle vaccines

Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus

The use of viral vectors to produce hepatitis B virus core particles in plants

Expression of HIV-1 antigens in plants as potential subunit vaccines

Canola oilseed-and Escherichia coli-derived hepatitis C virus (HCV) core proteins adjuvanted with oil bodies, induced robust Th1-oriented immune responses in immunized mice

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Improvement of PVX/CMV CP expression tool for display of short foreign antigens

Tobacco plants contribute key ingredient for COVID-19 Vaccine

Foliar extracts from transgenic tomato plants expressing the structural polyprotein, P1-2A, and protease, 3C, from foot-andmouth disease virus elicit a protective response in guinea pigs

Epitope presentation of dengue viral envelope glycoprotein domain III on hepatitis B core protein virus-like particles produced in Nicotiana benthamiana

The pEAQ vector series: the easy and quick way to produce recombinant proteins in plants

Improving plant transient expression through the rational design of synthetic 5 0 and 3 0 untranslated regions

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-two randomized phase II clinical trials in 18 to 49 andC 50 years old adults

Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design

Plant-made dengue virus-like particles produced by coexpression of structural and non-structural proteins induce a humoral immune response in mice

Factors associated with vaccination for hepatitis B, pertussis, seasonal and pandemic influenza among French general practitioners: a 2010 survey

Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein

Virus-like particles in vaccine development

Hepatitis B core-based virus-like particles to present heterologous epitopes

Will plant-made biopharmaceuticals play a role in the fight against COVID-19?

Extremely high-level and rapid transient protein production in plants without the use of viral replication

Current status of viral expression systems in plants and perspectives for oral vaccines development

Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies

Virus-like particles production in green plants

An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles

Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen

Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines

High-level expression of the HIV-1 Pr55 gag polyprotein in transgenic tobacco chloroplasts

Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops

From SARS to MERS, thrusting coronaviruses into the spotlight

Immunogenicity of peptide fusions to hepatitis B virus core antigen

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous humanlike N-glycan structure

Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous b1, 4-galactosylated N-glycan profile

Immunogenicity of transgenic plant-derived hepatitis B surface antigen

A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling

The use of transient expression systems for the rapid production of virus-like particles in plants

Plant molecular farming: much more than medicines

Molecular farming in plants: host systems and expression technology

Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16

Combating human viral diseases: will plant-based vaccines be the answer? Vaccines

Plant-derived vaccines: an approach for affordable vaccines against cervical cancer

Molecular epidemiology and phylogenetic analysis of a marine fish infectious spleen and kidney necrosis virus-like (ISKNV-like) virus

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

2020) Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (C 65 years): two multicentre, randomised phase 3 trials

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Immunoabsorbent nanoparticles based on a tobamovirus displaying protein A

The humanization of N-glycosylation pathways in yeast

SARS-CoV-2 evolution and vaccines: cause for concern?

Phase shift from a coral to a corallimorph-dominated reef associated with a shipwreck on Palmyra Atoll

Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus

Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice

Plants as factories for human pharmaceuticals: applications and challenges

Efficient production of chimeric hepatitis B virus-like particles bearing an epitope of hepatitis E virus capsid by transient expression in Nicotiana benthamiana

Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus

Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses

Coronaviruses-drug discovery and therapeutic options

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgements The authors would like to acknowledge the Plant Virology Research Center, Shiraz University, Shiraz, Iran.Author contributions FH and MK: Writing the original draft; MH-D and SK: Reviewing and editing; AA and MHE: Reviewing; DR: Reviewing and English editing. All authors are in agreement with the content of the manuscript. The work described has not been submitted elsewhere for publication, and all the authors have approved the enclosed manuscript.